Many have declared that molecules are the new microchip. But what does that mean and can synthetic biology address issues from climate change to chronic disease and food scarcity? At our Research Conference, Andrew Hessel helped us understand the potential as well as the risks that might come from developments in this field.
Novo Nordisk has become a household name thanks to Wegovy and Ozempic. What are the risks that stem from that attention, and just how significant is the long-term opportunity? In the first of a series of Digging Deeper conversations, Investment Manager Lindsay Scott shares her thoughts on the obesity and diabetes markets.
In April, LVMH became the first European company to surpass a market capitalisation of US$500 billion. But LVMH isn’t the only global leading company in France. In late May, members of our Research team headed to the country to meet some of those leaders and to take the temperature on the corporate mood.
In our latest quarterly podcast investment managers Paul Loudon and Lindsay Scott discuss the ground-breaking and often controversial obesity drugs that have been developed by Novo Nordisk and Eli Lilly. They also consider current goings-on in China and share insights from recent research debates.
Energy economist and historian, Peter Tertzakian summarises his thoughts on investing in energy today. The outlook is undoubtedly uncertain but sharing lessons from history and appreciation of the risks, Peter shared his optimism around the change to come, and the investment opportunities.
The information in this area of the website is intended for use by Institutional Investors and Consultants only. It is not intended for use by other investors including members of the general public.
By clicking “Yes” you hereby acknowledge, agree and represent to Walter Scott & Partners Limited that you are an Institutional Investor/Consultant and that you have read and understood the Terms and Conditions which apply.
The information contained on this page is not appropriate for, and should not be used or relied upon by, Retail Investors.
By clicking “No” you will be redirected to our Homepage.
Walter Scott & Partners Limited offers a variety of services intended solely for Institutional Clients from certain countries or regions. We do not offer these services outside of these intended countries or regions. Your country of legal residence will determine the services available to you. The information provided does not constitute an offer of or solicitation for purchase or sale of securities or provision of any investment services.